Compositions containing histamine-H2-receptor antagonists at low dosage
First Claim
1. A pharmaceutical composition for treating gastric disorders, said composition comprising a histamine H2 -receptor antagonist and an antacid, wherein the composition is optimally buffered to confer a pH substantially equal to that of the pKa of the histamine H2 -receptor antagonist and promote local absorption of the H2 -receptor antagonist, characterized in that the dose of histamine H2 -receptor antagonist per unit dosage form is less than 25 mg, provided that the composition does not contain sodium polyacrylate.
0 Assignments
0 Petitions
Accused Products
Abstract
Compositions for oral administration for the treatment of gastric disorders comprising histamine H2 -receptor antagonist and antacid, optionally buffered to promote local absorption of the H2 -receptor antagonist, wherein the quantity of H2 -receptor antagonist per unit dosage form is less than 25 mg.
39 Citations
10 Claims
- 1. A pharmaceutical composition for treating gastric disorders, said composition comprising a histamine H2 -receptor antagonist and an antacid, wherein the composition is optimally buffered to confer a pH substantially equal to that of the pKa of the histamine H2 -receptor antagonist and promote local absorption of the H2 -receptor antagonist, characterized in that the dose of histamine H2 -receptor antagonist per unit dosage form is less than 25 mg, provided that the composition does not contain sodium polyacrylate.
-
10. A method of treating gastric disorders comprising orally administering to a sufferer an effective amount of a pharmaceutical composition, said composition comprising a histamine H2 -receptor antagonist and an antacid, wherein the composition is optimally buffered such that the equilibrium pH, the acid neutralizing capacity and the gastric residence time values confer a pH level substantially equal to that of the pKa of the histamine H2 -receptor antagonist, characterized in that the dose of histamine H2 -receptor antagonist per unit dosage form is less than 25 mg, provided that the composition does not contain sodium polyacrylate.
Specification